Wilschut JC - Search Results

1

Nanoaggregates of micropurified lipopolysaccharide identified using dynamic light scattering, zeta potential measurement, and TLR4 signaling activity.

Hardy E, Kamphuis T, Japaridze A, Wilschut JC, Winterhalter M. Hardy E, et al. Among authors: wilschut jc. Anal Biochem. 2012 Nov 15;430(2):203-13. doi: 10.1016/j.ab.2012.08.027. Epub 2012 Sep 6. Anal Biochem. 2012. PMID: 22960012

2

A virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A provides protection against viral challenge without priming for enhanced disease in cotton rats.

Kamphuis T, Stegmann T, Meijerhof T, Wilschut J, de Haan A. Kamphuis T, et al. Influenza Other Respir Viruses. 2013 Nov;7(6):1227-36. doi: 10.1111/irv.12112. Epub 2013 Apr 10. Influenza Other Respir Viruses. 2013. PMID: 23575113 Free PMC article.

3

Lipopeptide-adjuvanted respiratory syncytial virus virosomes: A safe and immunogenic non-replicating vaccine formulation.

Stegmann T, Kamphuis T, Meijerhof T, Goud E, de Haan A, Wilschut J. Stegmann T, et al. Vaccine. 2010 Aug 2;28(34):5543-50. doi: 10.1016/j.vaccine.2010.06.041. Epub 2010 Jun 25. Vaccine. 2010. PMID: 20600502

4

Immunogenicity and protective capacity of a virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice.

Kamphuis T, Meijerhof T, Stegmann T, Lederhofer J, Wilschut J, de Haan A. Kamphuis T, et al. PLoS One. 2012;7(5):e36812. doi: 10.1371/journal.pone.0036812. Epub 2012 May 9. PLoS One. 2012. PMID: 22590614 Free PMC article.

5

Efficacy and safety of an intranasal virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice and cotton rats.

Kamphuis T, Shafique M, Meijerhof T, Stegmann T, Wilschut J, de Haan A. Kamphuis T, et al. Vaccine. 2013 Apr 19;31(17):2169-76. doi: 10.1016/j.vaccine.2013.02.043. Epub 2013 Mar 13. Vaccine. 2013. PMID: 23499594

6

The virosome concept for influenza vaccines.

Huckriede A, Bungener L, Stegmann T, Daemen T, Medema J, Palache AM, Wilschut J. Huckriede A, et al. Vaccine. 2005 Jul 8;23 Suppl 1:S26-38. doi: 10.1016/j.vaccine.2005.04.026. Vaccine. 2005. PMID: 16026906 Review.

7

The role of membrane fusion activity of a whole inactivated influenza virus vaccine in (re)activation of influenza-specific cytotoxic T lymphocytes.

Budimir N, Meijerhof T, Wilschut J, Huckriede A, de Haan A. Budimir N, et al. Vaccine. 2010 Dec 6;28(52):8280-7. doi: 10.1016/j.vaccine.2010.10.007. Epub 2010 Oct 19. Vaccine. 2010. PMID: 20965298

8

Induction of mucosal and systemic immunity against respiratory syncytial virus by inactivated virus supplemented with TLR9 and NOD2 ligands.

Shafique M, Wilschut J, de Haan A. Shafique M, et al. Vaccine. 2012 Jan 11;30(3):597-606. doi: 10.1016/j.vaccine.2011.11.054. Epub 2011 Nov 24. Vaccine. 2012. PMID: 22120195

9

Effect of viral membrane fusion activity on antibody induction by influenza H5N1 whole inactivated virus vaccine.

Geeraedts F, ter Veer W, Wilschut J, Huckriede A, de Haan A. Geeraedts F, et al. Vaccine. 2012 Oct 5;30(45):6501-7. doi: 10.1016/j.vaccine.2012.07.036. Epub 2012 Jul 27. Vaccine. 2012. PMID: 22841974

10

Evaluation of an intranasal virosomal vaccine against respiratory syncytial virus in mice: effect of TLR2 and NOD2 ligands on induction of systemic and mucosal immune responses.

Shafique M, Meijerhof T, Wilschut J, de Haan A. Shafique M, et al. PLoS One. 2013 Apr 8;8(4):e61287. doi: 10.1371/journal.pone.0061287. Print 2013. PLoS One. 2013. PMID: 23593453 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

241 results

Search Page

Filters